195 related articles for article (PubMed ID: 32699541)
1. Developing Nanoceria-Based pH-Dependent Cancer-Directed Drug Delivery System for Retinoblastoma.
Gao R; Mitra RN; Zheng M; Wang K; Dahringer JC; Han Z
Adv Funct Mater; 2018 Dec; 28(52):. PubMed ID: 32699541
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Therapeutic Potential of Nanoceria against Cancer: An Update.
Zahra D; Javaid A; Iqbal M; Akbar I; Ashfaq UA
Crit Rev Ther Drug Carrier Syst; 2021; 38(5):1-26. PubMed ID: 34375511
[TBL] [Abstract][Full Text] [Related]
3. Nanoceria: an innovative strategy for cancer treatment.
Tang JLY; Moonshi SS; Ta HT
Cell Mol Life Sci; 2023 Jan; 80(2):46. PubMed ID: 36656411
[TBL] [Abstract][Full Text] [Related]
4. Combinatory Cancer Therapeutics with Nanoceria-Capped Mesoporous Silica Nanocarriers through pH-triggered Drug Release and Redox Activity.
Singh RK; Patel KD; Mahapatra C; Parthiban SP; Kim TH; Kim HW
ACS Appl Mater Interfaces; 2019 Jan; 11(1):288-299. PubMed ID: 30539634
[TBL] [Abstract][Full Text] [Related]
5. Endocytosis of cerium oxide nanoparticles and modulation of reactive oxygen species in human ovarian and colon cancer cells.
Vassie JA; Whitelock JM; Lord MS
Acta Biomater; 2017 Mar; 50():127-141. PubMed ID: 27940194
[TBL] [Abstract][Full Text] [Related]
6. Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer.
Subramanian N; Raghunathan V; Kanwar JR; Kanwar RK; Elchuri SV; Khetan V; Krishnakumar S
Mol Vis; 2012; 18():2783-95. PubMed ID: 23213278
[TBL] [Abstract][Full Text] [Related]
7. Nanoceria-mediated delivery of doxorubicin enhances the anti-tumour efficiency in ovarian cancer cells via apoptosis.
Das J; Choi YJ; Han JW; Reza AMMT; Kim JH
Sci Rep; 2017 Aug; 7(1):9513. PubMed ID: 28842609
[TBL] [Abstract][Full Text] [Related]
8. Targeted Delivery and Redox Activity of Folic Acid-Functionalized Nanoceria in Tumor Cells.
Vassie JA; Whitelock JM; Lord MS
Mol Pharm; 2018 Mar; 15(3):994-1004. PubMed ID: 29397735
[TBL] [Abstract][Full Text] [Related]
9. Design and Fabrication of Multifunctional Sericin Nanoparticles for Tumor Targeting and pH-Responsive Subcellular Delivery of Cancer Chemotherapy Drugs.
Huang L; Tao K; Liu J; Qi C; Xu L; Chang P; Gao J; Shuai X; Wang G; Wang Z; Wang L
ACS Appl Mater Interfaces; 2016 Mar; 8(10):6577-85. PubMed ID: 26855027
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biomedical applications of nanoceria, a redox active nanoparticle.
Thakur N; Manna P; Das J
J Nanobiotechnology; 2019 Jul; 17(1):84. PubMed ID: 31291944
[TBL] [Abstract][Full Text] [Related]
11. Redox Active Cerium Oxide Nanoparticles: Current Status and Burning Issues.
Lord MS; Berret JF; Singh S; Vinu A; Karakoti AS
Small; 2021 Dec; 17(51):e2102342. PubMed ID: 34363314
[TBL] [Abstract][Full Text] [Related]
12. pH-Dependent Activity of Dextran-Coated Cerium Oxide Nanoparticles on Prohibiting Osteosarcoma Cell Proliferation.
Alpaslan E; Yazici H; Golshan NH; Ziemer KS; Webster TJ
ACS Biomater Sci Eng; 2015 Nov; 1(11):1096-1103. PubMed ID: 33429551
[TBL] [Abstract][Full Text] [Related]
13. ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer.
Yi H; Lu W; Liu F; Zhang G; Xie F; Liu W; Wang L; Zhou W; Cheng Z
J Nanobiotechnology; 2021 May; 19(1):134. PubMed ID: 33975609
[TBL] [Abstract][Full Text] [Related]
14. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic activity of heparin functionalised cerium oxide nanoparticles.
Lord MS; Tsoi B; Gunawan C; Teoh WY; Amal R; Whitelock JM
Biomaterials; 2013 Nov; 34(34):8808-18. PubMed ID: 23942211
[TBL] [Abstract][Full Text] [Related]
16. Intracellular antioxidants dissolve man-made antioxidant nanoparticles: using redox vulnerability of nanoceria to develop a responsive drug delivery system.
Muhammad F; Wang A; Qi W; Zhang S; Zhu G
ACS Appl Mater Interfaces; 2014; 6(21):19424-33. PubMed ID: 25312332
[TBL] [Abstract][Full Text] [Related]
17. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
Zhang T; Liu H; Li Y; Li C; Wan G; Chen B; Li C; Wang Y
Acta Biomater; 2019 Nov; 99():412-425. PubMed ID: 31494294
[TBL] [Abstract][Full Text] [Related]
18. Combination Therapy of NSCLC Using Hsp90 Inhibitor and Doxorubicin Carrying Functional Nanoceria.
Sulthana S; Banerjee T; Kallu J; Vuppala SR; Heckert B; Naz S; Shelby T; Yambem O; Santra S
Mol Pharm; 2017 Mar; 14(3):875-884. PubMed ID: 28081601
[TBL] [Abstract][Full Text] [Related]
19. Near-infrared light triggered drug delivery system for higher efficacy of combined chemo-photothermal treatment.
Chen Y; Li H; Deng Y; Sun H; Ke X; Ci T
Acta Biomater; 2017 Mar; 51():374-392. PubMed ID: 28088668
[TBL] [Abstract][Full Text] [Related]
20. pH/ROS dual-responsive supramolecular polypeptide prodrug nanomedicine based on host-guest recognition for cancer therapy.
Ding Y; Wang C; Ma Y; Zhu L; Lu B; Wang Y; Wang J; Chen T; Dong CM; Yao Y
Acta Biomater; 2022 Apr; 143():381-391. PubMed ID: 35272024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
